RT Journal Article
T1 The Role of Statins on Helicobacter pylori Eradication: Results from the European Registry on the Management of H. pylori (Hp-EuReg).
A1 Caldas, María
A1 Pérez-Aisa, Ángeles
A1 Tepes, Bojan
A1 Keco-Huerga, Alma
A1 Bujanda, Luis
A1 Lucendo, Alfredo J
A1 Rodrigo, Luis
A1 Vaira, Dino
A1 Fernández-Salazar, Luis
A1 Huguet, Jose M
A1 Pérez-Lasala, Jorge
A1 Jurecic, Natasa Brglez
A1 Fadeenko, Galina
A1 Barrio, Jesús
A1 Areia, Miguel
A1 Ortuño, Juan
A1 Pellicano, Rinaldo
A1 Leja, Marcis
A1 Molina-Infante, Javier
A1 Bogomolov, Pavel
A1 Alekseenko, Sergey
A1 Domínguez-Cajal, Manuel
A1 Gómez-Camarero, Judith
A1 Ntouli, Vassiliki
A1 Martínez-Domínguez, Samuel J
A1 Ruiz-Zorrilla, Rafael
A1 Núñez, Oscar
A1 Sarsenbaeva, Aiman Silkanovna
A1 Almela, Pedro
A1 Phull, Perminder
A1 Espada, Marta
A1 Puig, Ignasi
A1 Nyssen, Olga P
A1 Mégraud, Francis
A1 O'Morain, Colm
A1 Gisbert, Javier P
A1 the Hp-EuReg Investigators, 
K1 Helicobacter pylori
K1 statins
K1 treatment
AB Statins could increase the effectiveness of Helicobacter pylori eradication therapies due to their anti-inflammatory effect. The aim of this study was to analyze the impact of this therapeutic association in real life. This is a multicenter, prospective, non-interventional study aimed at evaluating the management of H. pylori by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap from 2013 to 2020. The association between statin use and H. pylori eradication effectiveness was evaluated through multivariate analysis. Overall, 9988 and 705 patients received empirical and culture-guided treatment, respectively. Overall, statin use was associated with higher effectiveness in the empirical group (OR = 1.3; 95%CI = 1.1-1.5), but no association was found with first-line treatment effectiveness (N = 7738); as an exception, statin use was specifically associated with lower effectiveness of standard triple therapy (OR = 0.76; 95%CI = 0.59-0.99). In the rescue therapy empirical group (N = 2228), statins were associated with higher overall effectiveness (OR = 1.9; 95%CI = 1.4-2.6). However, sub-analyses by treatment schemes only confirmed this association for the single-capsule bismuth quadruple therapy (OR = 2.8; 95%CI = 1.3-5.7). No consistent association was found between statin use and H. pylori therapy effectiveness. Therefore, the addition of statins to the usual H. pylori treatment cannot be currently recommended to improve cure rates.
SN 2079-6382
YR 2021
FD 2021-08-11
LK http://hdl.handle.net/10668/18414
UL http://hdl.handle.net/10668/18414
LA en
DS RISalud
RD Mar 15, 2025